R&D | May 14, 2026
Merck to showcase 100+ oncology studies at 2026 ASCO meeting
Highlighting KEYTRUDA & expanding cancer pipeline
Highlighting KEYTRUDA & expanding cancer pipeline
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Pharma giant targets new standards of care
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
